TEVA-NAPROXEN 500 MG
NAPROXEN : 500 MG · DIN 00589861 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-NAPROXEN?
TEVA-NAPROXEN 500 MG contains NAPROXEN : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 00589861, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Aug-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00589861 |
|---|---|
| Brand name | TEVA-NAPROXEN |
| Generic / active ingredient | NAPROXEN : 500 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AE02 NAPROXEN |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Aug-2010 |
| Original market date | 1983-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AE02 NAPROXEN. 31 of 125 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALEVE BACK AND BODY PAIN | 220 MG | CAPSULE | BAYER INC | MARKETED | DIN 02436337 |
| ALEVE CAPLETS | 220 MG | TABLET | BAYER INC | MARKETED | DIN 02301733 |
| ALEVE LIQUID GELS | 220 MG | CAPSULE | BAYER INC | MARKETED | DIN 02361795 |
| ALEVE NIGHTTIME | 220 MG | TABLET | BAYER INC | MARKETED | DIN 02444593 |
| ANAPROX | 275 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02162725 |
| ANAPROX DS | 550 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02162717 |
| APO-NAPRO-NA | 275 MG | TABLET | APOTEX INC | MARKETED | DIN 00784354 |
| APO-NAPRO-NA DS | 550 MG | TABLET | APOTEX INC | MARKETED | DIN 01940309 |
| APO-NAPROXEN | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 00522651 |
| APO-NAPROXEN | 375 MG | TABLET | APOTEX INC | MARKETED | DIN 00600806 |
Who else supplies NAPROXEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NAPROXEN appears in 1493 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.